Blog

Giuseppe Banna: Enjoyed being part of the EAU 2025 Symposium

Giuseppe Banna/LinkedIn

Mar 24, 2025, 09:15

Giuseppe Banna: Enjoyed being part of the EAU 2025 Symposium

Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn:

“I truly enjoyed being part of this insightful symposium with Verane Achard, Teresa Lopez, and Alberto Briganti at EAU25, discussing relugolix, an LHRH antagonist with lower cardiovascular risk and rapid, profound castration and PSA decline.

It makes a valuable option in metastatic hormone-sensitive prostate cancer (mHSPC), particularly in the context of treatment de-escalation strategies. – Giuseppe Banna

Great discussions and perspectives – looking forward to continuing the conversation!”

Giuseppe Banna

Alberto Briganti cancer cardiovascular risk EAU25 Giuseppe Banna Metastatic Hormone-sensitive Prostate Cancer OncoDaily Oncology prostate cancer Teresa Lopez Verane Achard

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action